Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522890 | 0.85 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL20093598 | 0.83 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL23677895 | 0.79 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL12982333 | 0.78 | CNR2 (0.42) | CNR2CNR1 | |
| SCHEMBL13496391 | 0.77 | NPC1 (0.46) | CNR2 | |
| SCHEMBL18494777 | 0.77 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL30613919 | 0.77 | CNR2 (0.68) | CNR2CNR1 | |
| SCHEMBL12981616 | 0.76 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL10685133 | 0.75 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL10583140 | 0.75 | CNR2 (0.55) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | CNR2 75/4885CNR1 106/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | CNR2 75/4885CNR1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.